Prime Medicine ($PRME) Stock Forecast: Down 9.0% Today

What is Prime Medicine?

Prime Medicine (PRME) is a biotech company specializing in innovative treatments for liver and lung diseases through prime editing technology. The company's stock faced a downtrend today despite recent progress in its lead programs.

Why is Prime Medicine going down?

PRME stock is down 9.0% on Mar 11, 2026 13:43

• Concerns may have arisen in the market regarding PRME's shift towards liver diseases, potentially impacting views on diversification and market prospects.
• Investors might be exercising caution despite positive mentions by LifeSci Capital, as PRME is well-funded until 2027, hinting at a longer timeline for generating revenue.
• The CEO's positive statements on potential FDA policy changes reducing costs for rare disease treatments may have been overlooked due to profit-taking or market uncertainties, contributing to the stock's bearish movement.

PRME Price Chart

PRME Technical Analysis

PRME News

Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway

Prime Medicine (PRME) is shifting its focus to its in vivo liver franchise, supported by a $191.4 million cash runway into 2027. Despite a net loss, the company is advancing lead programs for Wilson Disease and Alpha-1 Antitrypsin Deficiency, expecting initial clinical data in 2027. Prime Medicine is also pursuing accelerated FDA approval for its CGD candidate, PM359, following positive Phase 1/2 data.

https://finviz.com/news/333184/prime-medicine-prme-focuses-on-liver-franchise-with-1914m-cash-runway

LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases

LifeSci Capital has initiated coverage on Prime Medicine (PRME), emphasizing its potential for "one-and-done" curative treatments for liver and lung diseases using its prime editing technology. The firm highlights the broad applicability of prime editing, which enables precise gene modifications to address a wide range of genetic disorders. This initiation suggests a positive outlook on Prime Medicine's platform and its therapeutic prospects.

https://www.msn.com/en-us/money/savingandinvesting/lifesci-capital-initiates-prime-medicine-prme-highlights-one-and-done-potential-in-liver-and-lung-diseases/ar-AA1Tmfyl?ocid=BingNewsVerp

Prime Medicine CEO: FDA's new rare disease policies will lower costs

The CEO of Prime Medicine stated that the FDA's new policies regarding rare diseases are expected to lead to lower costs. This suggests a shift in regulatory approach aimed at making treatments for rare conditions more affordable, potentially benefiting both patients and the pharmaceutical industry.

https://firstwordpharma.com/story/7127336

Trending Today

XRP ($XRP) Crypto Forecast: Up 6.6% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.1% Today

MicroVision Inc. ($MVIS) Stock Forecast: Up 5.8% Today

Xerox Corporation ($XRX) Stock Forecast: Down 5.1% Today

Bruker Corporation ($BRKR) Stock Forecast: Down 4.8% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.0% Today

Helmerich & Payne Inc. ($HP) Stock Forecast: Up 3.6% Today

Coupang LLC ($CPNG) Stock Forecast: Up 3.5% Today

Fastly Inc. ($FSLY) Stock Forecast: Down 5.0% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 6.2% Today

Prime Medicine Price History

24.01.2026 - PRME Stock was up 11.4%

• Jacob Funds' investment in Prime Medicine reflects growing confidence in the company's potential to revolutionize the treatment of various diseases through its precise gene editing capabilities.
• The positive results from Prime Medicine's first clinical trial are likely driving investor optimism and contributing to the bullish movement in PRME stock.
• The market's reaction suggests that investors see Prime Medicine as a promising player in the gene therapy space, with the potential for significant growth and impact in the healthcare industry.

03.02.2026 - PRME Stock was down 6.1%

• HighTower Advisors LLC and other institutional investors significantly increased their stakes in PRME, indicating confidence in the company's long-term prospects. However, this did not prevent the bearish movement in the market.
• The announcement of Prime Medicine's participation in investor conferences and the positive reception from investors initially boosted the stock price by 7.83%. However, this momentum was not sustained, leading to the bearish movement.
• The surge in call options trading and bullish sentiment among traders drove PRME shares up initially by 4.8%. Despite this positive activity, the overall market sentiment turned bearish.
• Participation in upcoming investor conferences to discuss Prime Medicine's innovative platform and therapeutic programs could potentially attract more investors in the future, but today's market movement seems to have been influenced by broader market trends rather than company-specific news.

04.01.2026 - PRME Stock was down 5.7%

• Despite a substantial US$110 million decrease in market cap for Prime Medicine, Inc. (PRME) last week, institutional investors show confidence in the company's strong long-term returns.
• Strong one-year gains of 44% potentially offset the recent market cap decline, displaying resilience amidst short-term market fluctuations.
• Institutional ownership stands at 44%, with significant insider holdings indicating optimism about the company's future, potentially explaining the lack of concern among investors regarding the recent market downturn.
• The stock price appears sensitive to institutional trading activities, underscoring the influence of their decisions on market movements and emphasizing the need to monitor institutional sentiment for insights into PRME's future performance.

06.02.2026 - PRME Stock was down 7.8%

• The bearish movement in PRME's stock today can be attributed to the company's ongoing financial struggles and widening losses, as highlighted by the recent quarterly report showing a significant net loss of $50.6 million.
• Despite an upgrade to a "strong-buy" rating by Lifesci Capital, the overall sentiment remains cautious among investors due to the company's consistent quarterly losses and projected revenue declines.
• The CEO's optimism about the FDA's new rare disease policies lowering costs may have provided some hope, but the market seems more focused on Prime Medicine's financial performance and the challenges it faces in sustaining operations.
• The company's focus on advancing its gene editing pipeline and engaging with the FDA for regulatory pathways could be potential catalysts for a turnaround in investor sentiment if successful in translating these efforts into positive clinical outcomes and revenue generation.

10.01.2026 - PRME Stock was down 5.1%

• Despite receiving a "Moderate Buy" consensus rating from seven brokerages, PRME's stock saw a significant decline.
• The average 12-month price target of $7.21 indicates optimism in the company's future performance, but the market reacted negatively.
• Institutional investors holding a substantial portion of the stock may have contributed to the heightened selling pressure, leading to the bearish movement.
• The disconnect between the positive analyst recommendations and the actual market performance suggests that external factors or unexpected news may have influenced the stock's decline.

22.00.2026 - PRME Stock was up 7.0%

• A significant increase in stake by Sumitomo Mitsui Trust Group Inc. by 127.7% in the third quarter reflects strong confidence in PRME's future prospects.
• The high institutional ownership of about 70.37% suggests strong support from large investors, potentially benefiting the stock price.
• Analysts' "Moderate Buy" rating and the average price target of $7.21 may have contributed to the positive sentiment, signaling promising growth potential for PRME.

05.02.2026 - PRME Stock was down 6.4%

• The CEO's positive remarks on FDA's new rare disease policies could potentially lead to lower costs for treatments, which might have raised concerns among investors about Prime Medicine's revenue prospects, contributing to the bearish market movement.
• Despite receiving a "strong-buy" rating from Lifesci Capital, Prime Medicine's reported losses in the last quarter and for the full year 2025, along with missing revenue estimates, have likely dampened investor sentiment and contributed to the bearish trend.
• The company's heavy spending phase, widening losses, and projected revenue declines as highlighted in the quarterly results may have reinforced the bearish narratives among investors, leading to a negative market movement for Prime Medicine.
• The affirmation of a cash runway into 2027 and the company's progress in advancing gene-editing therapies could be positive long-term indicators, but the immediate focus seems to be on the financial performance, causing the bearish sentiment in the market.

27.00.2026 - PRME Stock was up 5.1%

• An analyst reaffirmed a "buy" rating for Prime Medicine (PRME.US) and kept a target price of $5.
• The positive analyst rating likely played a role in the stock's upward movement.
• Investor optimism about Prime Medicine's gene editing therapies and the analyst's target price could have influenced the stock's performance.
• The news of the analyst's rating may have increased investor confidence in the company's future, leading to heightened buying activity and an increase in the stock price.

26.01.2026 - PRME Stock was up 5.2%

• Unusual options trading activity with a significant increase in call options indicates a bullish sentiment among traders.
• The company's "Moderate Buy" consensus from analysts and substantial institutional investor stake add to the positive market momentum.
• Participation in upcoming investor conferences to discuss its Prime Editing platform and therapeutic programs likely boosted investor confidence, contributing to the stock's upward trend.

03.01.2026 - PRME Stock was down 8.7%

• Despite Prime Medicine, Inc. experiencing a US$110 million decrease in market cap last week, institutional investors have still benefited from 36% gains over the past year.
• The high sensitivity of the stock price to institutional trading actions, with institutions holding a substantial 44% ownership in the company, likely contributed to the bearish movement.
• The concentration of ownership among the top 8 shareholders, who collectively own more than half of the company's shares, could have influenced the market sentiment and led to the downward trend in PRME stock.
• The long-term gains for institutional investors juxtaposed with the recent market cap decrease may indicate a temporary setback rather than a fundamental issue with the company, potentially offering a buying opportunity for savvy investors looking at the bigger picture.

09.02.2026 - PRME Stock was up 7.0%

• The bullish movement in PRME stock today can be attributed to an initiation of coverage, highlighting the one-and-done potential of Prime Medicine's prime editing technology for liver and lung diseases. This positive outlook on the company's therapeutic prospects likely boosted investor confidence.
• Additionally, the CEO's comments on the FDA's new rare disease policies potentially lowering costs for treatments could have further contributed to the bullish sentiment surrounding PRME.
• Despite the quarterly loss reported by Prime Medicine, the upgraded "strong-buy" rating and the promising full-year financial results and business updates seem to have outweighed the bearish narratives, driving the stock's upward movement.

11.02.2026 - PRME Stock was down 9.0%

• Concerns may have arisen in the market regarding PRME's shift towards liver diseases, potentially impacting views on diversification and market prospects.
• Investors might be exercising caution despite positive mentions by LifeSci Capital, as PRME is well-funded until 2027, hinting at a longer timeline for generating revenue.
• The CEO's positive statements on potential FDA policy changes reducing costs for rare disease treatments may have been overlooked due to profit-taking or market uncertainties, contributing to the stock's bearish movement.